Results 21 to 30 of about 28,689 (318)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation

Frontiers in Pharmacology, 2022
Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary complication of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we retrospectively identified seven patients
Xiaoyu Zhang, Xiaoli Zhao, Yuyan Shen, Yuanyuan Shi, Lining Zhang, Mengze Hao, Fei Zhao, Rongli Zhang, Jialin Wei, Sizhou Feng, Yi He, Erlie Jiang, Mingzhe Han   +12 more
doaj   +1 more source

Ruxolitinib in Aicardi-Goutières syndrome

Metabolic Brain Disease, 2021
Abstract Aicardi Goutières Syndrome (AGS) is a monogenic leukodystrophy with pediatric onset, clinically characterized by a variable degree of neurologic impairment. It belongs to a group of condition called type I interferonopathies that are characterized by abnormal overproduction of interferon alpha, an inflammatory cytokine which action is ...
Francesca Penagini, Clara E. Antonello, Cecilia Parazzini, Gian Vincenzo Zuccotti, Gian Vincenzo Zuccotti, Pierangelo Veggiotti, Pierangelo Veggiotti, Jessica Garau, Dario Dilillo, Simona Orcesi, Eleonora Mura, Giana Izzo, Daisy Sproviero, Cristina Cereda, Silvia Masnada, Davide Tonduti   +15 more
openaire   +5 more sources

Coccidioidomycosis in Patients Treated With Ruxolitinib [PDF]

Open Forum Infectious Diseases, 2020
Abstract We report 8 cases of coccidioidomycosis associated with ruxolitinib treatment. Among 135 patients living in the coccidioidal-endemic region receiving ruxolitinib, 5 cases were diagnosed after starting and 4 had extrathoracic dissemination.
Roberto L. Patron, Neil M Ampel, Janis E. Blair, Holenarasipur R. Vikram, Kathryn E Kimes, Fionna F Feller, Juan Gea Banacloche, Yael Kusne   +7 more
openaire   +3 more sources

Pharmacokinetic Monitoring of JAK Inhibitor and Tacrolimus for Safe and Effective Management of Graft-Versus-Host Disease After Pediatric Liver Transplantation. [PDF]

Pediatr Transplant
ABSTRACT Background and Aim Though liver transplantation (LT) is effective for pediatric patients with end‐stage liver disease, it is associated with complications such as graft‐versus‐host disease (GVHD). In part due to its rarity and lack of standardized therapy, post‐LT GVHD is associated with a high mortality rate.
Sawada K, Khandelwal P, Davies SM, Crooker A, Mizuno T, Asai A.   +5 more
europepmc   +2 more sources

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

Efficacy of ruxolitinib for myelofibrosis [PDF]

Expert Opinion on Pharmacotherapy, 2014
The discovery of the activating JAK2 V617F mutation in patients with myelofibrosis (MF) led to the development of JAK2 inhibitors. The first such inhibitor to enter clinical trials was ruxolitinib . This review summarizes preclinical and clinical data of ruxolitinib in MF.A literature search through Medline employing the terms 'ruxolitinib ...
Srdan Verstovsek, Fabio P.S. Santos
openaire   +3 more sources

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review

Clinical Pharmacokinetics, 2023
Ruxolitinib is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Ruxolitinib is used to treat myelofibrosis, polycythemia vera and steroid-refractory graft-versus-host disease in the setting of allogeneic stem-cell transplantation.
T. Y. J. Appeldoorn, T. H. Oude Munnink, L. M. Morsink, M. N. Lub-de Hooge, D. J. Touw   +4 more
openaire   +3 more sources

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis

Hematology, 2022
Objectives Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the ...
Timothy Devos, Dominik Selleslag, Nikki Granacher, Violaine Havelange, Fleur Samantha Benghiat   +4 more
doaj   +1 more source

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

Frontiers in Endocrinology, 2023
Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose
Douglas Tremblay, Mikaela Dougherty, John Mascarenhas, Emily Jane Gallagher   +3 more
doaj   +1 more source